StocksDeepDive
Snapshot · Russell 3000 · generated 2026-09-19 21:53 UTC

AKBA — Akebia Therapeutics, Inc.

UNDERVALUED (MOS +52.5%) · Quality 15/100

Price
0.92
Intrinsic value
1.93
Margin of safety
+52.5%
Implied growth (reverse DCF)
-9.8%
model assumes +0.0%
Value Score
31.2
Quality
15
Psychology
35.9
Discovery
16.1
price/volume attention only
Moat score
64.2
erosion: none

Value Score: bottom 48% of Russell 3000 · Quality: bottom 9%

Open the interactive Deep Dive for AKBA →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/AKBA - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is AKBA undervalued?

As of 2026-09-19, AKBA trades at 0.92 against a computed intrinsic value of 1.93 (+52.5% margin of safety) - StocksDeepDive's valuation label for this is UNDERVALUED. This is a described calculation from public data, not a recommendation.

What is Akebia Therapeutics, Inc.'s Value Score?

Akebia Therapeutics, Inc.'s Value Score is 31.2 as of 2026-09-19 - it combines value, quality, crowd psychology and market attention into one number.